Case histories, magic bullets and the state of drug discovery
- 1 August 2006
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 5 (8) , 635-640
- https://doi.org/10.1038/nrd2084
Abstract
The case histories of five modern drugs are taken as a basis for reflection on the state of drug discovery. Two issues intimately associated with drug research are highlighted: the nature of the intellectual process leading to new discoveries; and the possibility that the principle of selective efficacy, which has guided drug research from its beginnings, might need modification, at least in some areas of pharmacotherapy.Keywords
This publication has 42 references indexed in Scilit:
- Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trialThe Lancet, 2004
- Cyclooxygenases: new forms, new inhibitors, and lessons from the clinicThe FASEB Journal, 2004
- The development of COX2 inhibitorsNature Reviews Drug Discovery, 2003
- The Coxibs, Selective Inhibitors of Cyclooxygenase-2New England Journal of Medicine, 2001
- Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2000
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Cyclooxygenases: Structural, Cellular, and Molecular BiologyAnnual Review of Biochemistry, 2000
- CYCLOOXYGENASES 1 AND 2Annual Review of Pharmacology and Toxicology, 1998
- Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase.Proceedings of the National Academy of Sciences, 1993
- Identification of a cyclooxygenase-related gene and its potential role in prostaglandin formationBiochemical and Biophysical Research Communications, 1989